Selective raf inhibition in cancer therapy

Vladimir Khazak, Igor Astsaturov, Ilya G. Serebriiskii, Erica A. Golemis

Research output: Contribution to journalReview articlepeer-review

65 Scopus citations


Over the past 5 years, the Raf kinase family has emerged as a promising target for protein-directed cancer therapy development. The goal of this review is to first provide a concise summary of the data validating Raf proteins as high-interest therapeutic targets. The authors then outline the mode of action of Raf kinases, emphasizing how Raf activities and protein interactions suggest specific approaches to inhibiting Raf. The authors then summarize the set of drugs, antisense reagents and antibodies available or in development for therapeutically targeting Raf or Raf-related proteins, as well as existing strategies combining these and other therapeutic agents. Finally, the authors discuss recent results from systems biology analyses that have the potential to increasingly guide the intelligent selection of combination therapies involving Raf-targeting agents and other therapeutics.

Original languageEnglish
Pages (from-to)1587-1609
Number of pages23
JournalExpert Opinion on Therapeutic Targets
Issue number12
StatePublished - Nov 2007


  • Antisense inhibitor
  • B-Raf
  • Cancer
  • Combination therapy
  • Epidermal growth factor
  • Kinase inhibitor
  • MEK
  • Ras
  • Signal transduction
  • Systems biology
  • c-RAF-1


Dive into the research topics of 'Selective raf inhibition in cancer therapy'. Together they form a unique fingerprint.

Cite this